Someone posted a link to a very interesting article on cancer and ageing.

From the article -

Quote:

---

Rapamycin, a drug typically used in post-organ transplant care, has had encouraging results in experiments by German researchers, extending the life span of laboratory mice. But Dudley Lamming, an Associate Professor of Medicine at the University of Wisconsin-Madison who’s conducted his own research on rapamycin, tells The Post it’s too soon to get excited.

“Suppressing the normal function of the immune system, which normally patrols for cancer, could actually cause an increase in cancer risk,” he says. “There are a growing number of people taking rapamycin ‘off label’ for anti-aging purposes, but as of yet, there is no evidence that rapamycin can extend healthy aging in humans.”
https://nypost.com/2024/07/28/lifestyle/how-i...nd-cancer/

---

When I proposed that leronlimab may act as moderate antiviral in Covid by disrupting the PI3K/AKT/ mTORC1 /4E-BP1 pathway dysregulating elF4E. With elF4E disrupted the COVID-19 virus 5' -end cap would be unable to separate it's mRNA and duplicate and had a doctor interested in Covid look at my theory, he mentioned that may be why scientists were looking at rapamycin.

From Lammings medical paper -

Quote:

---

These results quite logically spurred substantial interest in the possibility that a potent chemical inhibitor of mTORC1, rapamycin, could extend lifespan. This was indeed the case, and there are now numerous studies showing that rapamycin can extend the lifespan not only of model organisms including yeast, worms and flies but also, as we detail below, of both wild-type mice and in many disease models.

Many of the side effects of rapamycin, which include immunosuppression, hyperlipidemia and hyperglycemia, have raised concerns about the feasibility of using rapamycin to promote healthy longevity in humans and have slowed clinical evaluation of mTOR inhibitors for diseases of aging
https://www.nature.com/articles/s43587-023-00416-y?

---

With leronlimab you'd eliminate these side effects while downregulating mTORC1.

Quote:

---

Brown tells the Post that macrophages have been the key to discovering the connection between inflammaging and cancer. Macrophages, and their precursors the monocytes, are “one of the most important types of immune cells for clearing infections,” he says. “But they’re also a key mediator of inflammation.”

Recent studies have found that cancers don’t just outsmart macrophages, they recruit them, producing chemicals that cause macrophages to suppress inflammation and promote tumor growth. “In fact, some cancers have more macrophages than cancer cells,” Brown says. Finding ways to control and redirect macrophages will have “a profound impact on cancer and potentially even aging,” he says.https://nypost.com/2024/07/28/lifestyle/how-i...nd-cancer/

---

Controlling macrophages is what leronlimab does.